**Table S10. LRχ² and p-values for CTS and 10-year signature in three groups of POLAR validation set for 0-5 and 5-10 years of follow-up.**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **All POLAR patients** | **Chemotherapy-treated** | **Chemotherapy-naïve** |
| 0-5 years |
| No. of patients (relapses) | n=308 (133) | n=128 (57) | n=180 (76) |
| Univariate | CTS | LRχ2 | 22.09 | 15.25 | 10.08 |
| P | <0.001 | <0.001 | 0.002 |
| 10-year signature | LRχ2 | 14.59 | 7.41 | 7.26 |
| P | <0.001 | 0.007 | 0.007 |
| Multivariable comparison | CTS+10-year signature vs CTS | ΔLRχ2 | 7.59 | 5.95 | 2.72 |
| P | 0.006 | 0.015 | 0.099 |
| 5-10 years |
| No. of patients (relapses) | n=285 (114) | n=113 (42) | n=172 (72) |
| Univariate | CTS | LRχ2 | 0.90 | 0.11 | 2.19 |
| P | 0.34 | 0.744 | 0.139 |
| 10-year signature | LRχ2 | 4.18 | 3.15 | 1.70 |
| P | 0.041 | 0.08 | 0.19 |
| Multivariable comparison | CTS+10-year signature vs CTS | ΔLRχ2 | 3.58 | 3.12 | 0.82 |
| P | 0.059 | 0.077 | 0.365 |

Both univariate and multivariable analyses are presented for years 0 to 10, years 0 to 5, and years 5 to 10 separately. Likelihood ratio test based on Cox proportional hazard models for univariate and multivariable analyses. Differences in likelihood ratio values (ΔLRχ2) were used. CTS was used as a covariate in the multivariable regressions. POLAR = molecular Predictors Of early versus LAte Recurrence in ER-positive breast cancer; CTS = clinical treatment score; LR = likelihood ratio.